A citation-based method for searching scientific literature

Solene De Talhouet, Julien Peron, Aurelie Vuilleumier, Alex Friedlaender, Valeria Viassolo, Aurélie Ayme, Alexandre Bodmer, Isabelle Treilleux, Noemie Lang, Jean- Christophe Tille, Pierre O Chappuis, Adrien Buisson, Sophie Giraud, Christine Lasset, Valerie Bonadona, Olivier Trédan, S Intidhar Labidi-Galy. Sci Rep 2020
Times Cited: 11







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
27

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
27

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
18

Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.
Manisha Ahir, Priyanka Upadhyay, Avijit Ghosh, Sushmita Sarker, Saurav Bhattacharya, Payal Gupta, Swatilekha Ghosh, Sreya Chattopadhyay, Arghya Adhikary. Biomater Sci 2020
13
18

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.
Jacob O'Brien, Heyam Hayder, Yara Zayed, Chun Peng. Front Endocrinol (Lausanne) 2018
752
18

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Yixiao Feng, Mia Spezia, Shifeng Huang, Chengfu Yuan, Zongyue Zeng, Linghuan Zhang, Xiaojuan Ji, Wei Liu, Bo Huang, Wenping Luo,[...]. Genes Dis 2018
142
18

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
166
18

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Rinske Drost, Kiranjit K Dhillon, Hanneke van der Gulden, Ingrid van der Heijden, Inger Brandsma, Cristina Cruz, Dafni Chondronasiou, Marta Castroviejo-Bermejo, Ute Boon, Eva Schut,[...]. J Clin Invest 2016
62
18

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Alice Lallo, Kristopher K Frese, Christopher J Morrow, Robert Sloane, Sakshi Gulati, Maximillian W Schenk, Francesca Trapani, Nicole Simms, Melanie Galvin, Stewart Brown,[...]. Clin Cancer Res 2018
74
18

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Jason P W Carey, Cansu Karakas, Tuyen Bui, Xian Chen, Smruthi Vijayaraghavan, Yang Zhao, Jing Wang, Keith Mikule, Jennifer K Litton, Kelly K Hunt,[...]. Cancer Res 2018
47
18

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
60
18

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Rinske Drost, Peter Bouwman, Sven Rottenberg, Ute Boon, Eva Schut, Sjoerd Klarenbeek, Christiaan Klijn, Ingrid van der Heijden, Hanneke van der Gulden, Ellen Wientjens,[...]. Cancer Cell 2011
156
18

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
28
18

Reverse the Resistance to PARP Inhibitors.
Yevgeniy Kim, Aleksei Kim, Ainur Sharip, Aigul Sharip, Juhong Jiang, Qing Yang, Yingqiu Xie. Int J Biol Sci 2017
41
18

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth, Christopher J Lord. Nat Rev Clin Oncol 2018
133
18

Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Erika A Newman, Fujia Lu, Daniela Bashllari, Li Wang, Anthony W Opipari, Valerie P Castle. Mol Cancer Res 2015
43
18

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Leslie A Parsels, David Karnak, Joshua D Parsels, Qiang Zhang, Jonathan Vélez-Padilla, Zachery R Reichert, Daniel R Wahl, Jonathan Maybaum, Mark J O'Connor, Theodore S Lawrence,[...]. Mol Cancer Res 2018
54
18

Novel inhibitors of poly(ADP-ribose) synthetase.
M R Purnell, W J Whish. Biochem J 1980
443
18

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
612
18

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
238
18

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
975
18

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ielizaveta Gorodetska, Iryna Kozeretska, Anna Dubrovska. J Cancer 2019
39
18

State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
255
18

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
18

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
564
18

Mechanism of eukaryotic homologous recombination.
Joseph San Filippo, Patrick Sung, Hannah Klein. Annu Rev Biochem 2008
998
18

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
18

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
18

BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
681
18

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Florence Coussy, Marion Lavigne, Leanne de Koning, Rania El Botty, Fariba Nemati, Adnan Naguez, Guillaume Bataillon, Berengère Ouine, Ahmed Dahmani, Elodie Montaudon,[...]. Theranostics 2020
12
9

Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Heather A Jacene, Pamela J DiPiro, Jennifer Bellon, Jiani Hu, Su-Chun Cheng, Laura Warren, Emily Schlosnagle, Faina Nakhlis, Jennifer M Rosenbluth, Eren Yeh,[...]. Breast Cancer Res Treat 2020
3
33

E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition.
Augustine Chen, Henry Beetham, Michael A Black, Rashmi Priya, Bryony J Telford, Joanne Guest, George A R Wiggins, Tanis D Godwin, Alpha S Yap, Parry J Guilford. BMC Cancer 2014
74
9

Effects of COL8A1 on the proliferation of muscle-derived satellite cells.
Xiaofan Li, Zhao Wang, Huili Tong, Yunqin Yan, Shufeng Li. Cell Biol Int 2018
9
11

KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Yoshihisa Tokumaru, Masanori Oshi, Eriko Katsuta, Li Yan, Vikas Satyananda, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe. Am J Cancer Res 2020
39
9

Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration.
Xihong Zhang, Min Lin, Kenneth L van Golen, Kiyoko Yoshioka, Kazuyuki Itoh, Douglas Yee. Breast Cancer Res Treat 2005
53
9

Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth.
Johanna Soikkeli, Piotr Podlasz, Miao Yin, Pirjo Nummela, Tiina Jahkola, Susanna Virolainen, Leena Krogerus, Päivi Heikkilä, Karl von Smitten, Olli Saksela,[...]. Am J Pathol 2010
76
9

Breast cancer quantitative proteome and proteogenomic landscape.
Henrik J Johansson, Fabio Socciarelli, Nathaniel M Vacanti, Mads H Haugen, Yafeng Zhu, Ioannis Siavelis, Alejandro Fernandez-Woodbridge, Miriam R Aure, Bengt Sennblad, Mattias Vesterlund,[...]. Nat Commun 2019
59
9

Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer.
Joanna Boguslawska, Hanna Kedzierska, Piotr Poplawski, Beata Rybicka, Zbigniew Tanski, Agnieszka Piekielko-Witkowska. J Urol 2016
52
9


The proteomic landscape of triple-negative breast cancer.
Robert T Lawrence, Elizabeth M Perez, Daniel Hernández, Chris P Miller, Kelsey M Haas, Hanna Y Irie, Su-In Lee, C Anthony Blau, Judit Villén. Cell Rep 2015
107
9

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
P Schmid, R Salgado, Y H Park, E Muñoz-Couselo, S B Kim, J Sohn, S-A Im, T Foukakis, S Kuemmel, R Dent,[...]. Ann Oncol 2020
53
9

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Y H Park, E Senkus-Konefka, S-A Im, G Pentheroudakis, S Saji, S Gupta, H Iwata, M Y Mastura, R Dent, Y-S Lu,[...]. Ann Oncol 2020
7
14

LncRNA RUSC1-AS1 promotes the proliferation of breast cancer cells by epigenetic silence of KLF2 and CDKN1A.
C-C Hu, Y-W Liang, J-L Hu, L-F Liu, J-W Liang, R Wang. Eur Rev Med Pharmacol Sci 2019
12
9

Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O Nielsen, Heikki Joensuu, E Aubrey Thompson, Saranya Chumsri. Clin Cancer Res 2020
3
33

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
Abderrahim El Guerrab, Mahchid Bamdad, Yves-Jean Bignon, Frédérique Penault-Llorca, Corinne Aubel. Sci Rep 2020
10
10



Significance of Tsukushi in lung cancer.
Tatsuya Yamada, Kunimasa Ohta, Yamato Motooka, Kosuke Fujino, Shinji Kudoh, Yuki Tenjin, Younosuke Sato, Akira Matsuo, Koei Ikeda, Makoto Suzuki,[...]. Lung Cancer 2019
6
16

Identifying the hub gene in gastric cancer by bioinformatics analysis and in vitro experiments.
Feiran Wang, Qiang Xue, Dong Xu, Yasu Jiang, Chong Tang, Xianchen Liu. Cell Cycle 2020
6
16

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Charissa Kim, Ruli Gao, Emi Sei, Rachel Brandt, Johan Hartman, Thomas Hatschek, Nicola Crosetto, Theodoros Foukakis, Nicholas E Navin. Cell 2018
262
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.